ResMed (RMD) continues to thrive in the
MedTech sector, consistently securing its position as a top growth and momentum stock.
Citi maintains a Buy Rating, with a target price of $330, reflecting the stock's growing investor interest. Recent discussions about RMD's CEO's pay and a U.S security probe have caused some fluctuation, but this has not significantly impacted the overall bullish outlook. Multiple
earnings estimates suggest that RMD will continue its trend of surpassing predictions. RMD's attractive returns,
strong revenue growth, and strategic acquisitions have fueled its increasing valuation. Notably, the launch of the Global Sleep Institute and the acquisition of VirtuOx further underscore the company's triumphant trajectory. ResMed's strategic maneuvers have not gone unnoticed; both
UBS and
Baird maintain a Buy Rating on the stock. Despite occasional losses, consistent returns and successful launches, investor confidence in ResMed remains high. ResMed has proven its strength with an impressive
8.52% upside potential and a well-respected position among institutional owners.
Resmed RMD News Analytics from Fri, 31 Jan 2025 08:00:00 GMT to Fri, 03 Oct 2025 19:51:17 GMT -
Innovation 7
- Information 9
- Rumor 5
